It also postponed taking up of incorporating HSBC's wholly-owned subsidiary, which will act as a trustee company to HSBC Mutual Fund, and allowing foreign direct investment (FDI) in the infrastructure subsidiary of Idea Cellular.
FIPB cleared seven FDI proposals worth Rs 290 crore. These included those of IMCD India, Samara Capital Partners Fund II, Reckitt Benckiser (India), Haymarket SAC Publishing (India), and Fincare Business Services, according to a statement by the finance ministry.
The statement said an application to increase foreign investment in Idea Cellular Infrastructure Services (ICISL) to 67.5 per cent was deferred by the panel, chaired by economic affairs secretary Shaktikanta Das.
ICISL is a wholly-owned subsidiary of Idea, which has become a foreign-owned company with more than 50 per cent overseas investment. As such, ICISL is also deemed to have foreign investment in excess of 50 per cent as a mirror image of its parent company.
The proposal was to take on record the increase of foreign investment in ICISL beyond 50 per cent and allow foreign investment in ICISL up to 67.5 per cent.
Besides, Quintillion Business Media's proposal for approval for the issuance of equity shares to Bloomberg has been deferred. Financial Times (India)'s proposal to transfer 99.99 per cent equity to Falstaff Singapore was also deferred. The proposal involved transfer of entire shareholding of Falstaff Singapore to Nikkei Inc. Among other deferred proposals are Morgan Stanley India Primary Dealer's proposal for increasing equity participation from 75 per cent to 100 per cent by way of transfer of equity shares from Morgan Stanley India Capital to Morgan Stanley Mauritius Co Ltd, by amending the earlier approval.
The investment proposals of HSBC Securities and Capital Markets (India)'s proposal to incorporate a wholly-owned subsidiary, which will act as a trustee company to HSBC Mutual Fund was also put off. The proposal involved permission for additional activities by HSBC InvestDirect Financial Services (India), a wholly owned subsidiary of HSBC Invest Direct (India).
The FIPB rejected five investment proposals including that of pharma company Sanofi-Synthelabo (India).
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)